Literature DB >> 8431003

Use of rifampin in nonstaphylococcal, nonmycobacterial disease.

A B Morris1, R B Brown, M Sands.   

Abstract

Rifampin has very broad antimicrobial properties with in vitro activities against many bacteria, mycobacteria, higher bacteria, chlamydia, fungi, parasites, and viruses (Table 1). The clinical use of rifampin is more limited, in part because of the lack of in vivo human clinical studies demonstrating its efficacy. Investigators have valid concerns regarding the emergence of resistance of mycobacteria if widespread use of rifampin becomes common, although this has not been well documented. Because rifampin obtains therapeutic levels intracellularly and is distributed widely throughout the body, the antibiotic potentially could be used on a broader scale, but more studies will be needed to demonstrate its clinical utility.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8431003      PMCID: PMC187595          DOI: 10.1128/AAC.37.1.1

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  90 in total

1.  Effects of rifampicin with and without isoniazid in rheumatoid arthritis.

Authors:  B McConkey; R D Situnayake
Journal:  J Rheumatol       Date:  1988-01       Impact factor: 4.666

2.  Folliculitis decalvans--response to rifampin.

Authors:  S J Brozena; L E Cohen; N A Fenske
Journal:  Cutis       Date:  1988-12

3.  Treatment with rifampicin for Pneumocystis carinii pneumonia.

Authors:  B Singh; R S Jones
Journal:  Ann Trop Paediatr       Date:  1984-03

4.  Controlled trial of rifampicin and ethambutol in Crohn's disease.

Authors:  J L Shaffer; S Hughes; B D Linaker; R D Baker; L A Turnberg
Journal:  Gut       Date:  1984-02       Impact factor: 23.059

5.  Combination antifungal chemotherapy for experimental disseminated candidiasis: lack of correlation between in vitro and in vivo observations with amphotericin B and rifampin.

Authors:  J D Ernst; M Rusnak; M A Sande
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

6.  Addition of rifampin to ticarcillin-tobramycin combination for the treatment of Pseudomonas aeruginosa infections: assessment in a neutropenic mouse model.

Authors:  J J Zuravleff; P Chervenick; V L Yu; R R Muder; W F Diven
Journal:  J Lab Clin Med       Date:  1984-06

7.  Treatment of uncomplicated gonorrhoea in women with a combination of rifampicin and erythromycin.

Authors:  A J Boakes; P S Loo; G L Ridgway; S Tovey; J D Oriel
Journal:  Br J Vener Dis       Date:  1984-10

8.  Rifampin-resistant meningococcal infection in a patient given rifampin chemoprophylaxis.

Authors:  P Berkey; K Rolston; A Zukiwski; G Gooch; G P Bodey
Journal:  Am J Infect Control       Date:  1988-12       Impact factor: 2.918

9.  Therapeutic efficacy and pharmacokinetic properties of rifampicin in a Bacteroides fragilis intra-abdominal abscess.

Authors:  K P Fu; E R Lasinski; H C Zoganas; E F Kimble; E A Konopka
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

10.  Local rifampicin in treatment of rhinoscleroma.

Authors:  A M Gamea
Journal:  J Laryngol Otol       Date:  1988-04       Impact factor: 1.469

View more
  3 in total

1.  Electron microscopy and serological features of a patient with Q fever prosthetic valve endocarditis.

Authors:  B J Isalska; A Curry; T N Stanbridge; D Tweddle; E O Caul
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

2.  In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.

Authors:  Yi-Fan Hu; Chang-Pan Liu; Nai-Yu Wang; Shou-Chuan Shih
Journal:  BMC Infect Dis       Date:  2016-08-24       Impact factor: 3.090

3.  Rising incidence of Enterococcus species in microbiological specimens from orthopedic patients correlates to increased use of cefuroxime: a study concentrating on tissue samples.

Authors:  Peter Christian Siesing; Jens Peter Alva-Jørgensen; Jakob Brodersen; Magnus Arpi; Poul Einar Jensen
Journal:  Acta Orthop       Date:  2013-04-17       Impact factor: 3.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.